^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | erfonrilimab (KN046) (PD-L1 inhibitor, CTLA4 inhibitor) + anbenitamab (KN026) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
Excerpt:
...- Histologically or cytologically confirmed, locally advanced HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma....
Trial ID:
Source:
Title:
1210P - The preliminary efficacy and safety of KN026 combined with KN046 treatment in HER2-positive locally advanced unresectable or metastatic gastric/gastroesophageal junction cancer without prior systemic treatment in a phase II study
Published date:
09/05/2022
Excerpt:
...a total of 31 HER2 positive locally advanced unresectable or metastatic gastric/gastroesophageal junction cancer (GC/GEJ) patients without prior systemic treatment were enrolled….The ORR was up to 77.8% (95% CI: 57.7, 91.4), and the DCR was 92.6% (95% CI: 75.7, 99.1)....KN026 combined with KN046 treatment had demonstrated outstanding efficacy and manageable safety in HER2 positive GC/GEJ patients without prior systemic treatment.
Trial ID:
Source:
Title:
1377P - Preliminary efficacy and safety results of KN026 (a HER2-targeted bispecific antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in patients (pts) with HER2-positive gastrointestinal tumors
Published date:
09/13/2021
Excerpt:
Among 25 efficacy evaluable pts, ORR was 86% (6/7, 95% CI: 42%-100%) in the first-line mGC/GEJ cohort....In the late line GC/GEJ cohort, mPFS was 8.4 mo and 12-month OS rates were 91.7%....KN026 combined with KN046 as a chemo-free regimen was safe and demonstrated potential superior clinical benefit to available standard of care in both treatment-naive and heavily pretreated HER2-postive gastrointestinal tumors.
Trial ID:
